Herpes Zoster Vaccines
Authors:
Open Access
- 30 September 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 224 (Supplement) , S429-S442
Abstract
Herpes zoster (HZ) affects approximately 1 in 3 persons in their lifetime, and the risk of HZ increases with increasing age. The most common, debilitating complication of HZ is the chronic neuropathic pain of postherpetic neuralgia (PHN). Two herpes zoster vaccines, a live-attenuated varicella-zoster virus (VZV) vaccine (zoster vaccine live [ZVL]; ZOSTAVAX [Merck]) and an adjuvanted VZV glycoprotein E (gE) subunit vaccine (recombinant zoster vaccine [RZV]; SHINGRIX [GlaxoSmithKline]) are licensed for the prevention of HZ and PHN in healthy older adults. The safety and efficacy of both vaccines has been demonstrated in clinical trials in immunocompetent adults and in selected immunocompromised persons and persons with immune-mediated diseases. Numerous real-world effectiveness studies have confirmed the safety and effectiveness of both ZVL and RZV. Recombinant zoster vaccine (RZV) is more effective for prevention of HZ than ZVL. Recombinant zoster vaccine is nonreplicating and is thus safe in immunocompromised persons. Additional zoster vaccines are in different stages of development. Wider distribution of safe and effective zoster vaccines will improve the health and well being of the rapidly growing population of older adults around the world.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases
This publication has 15 references indexed in Scilit:
- Herpes zoster vaccine live: A 10 year review of post-marketing safety experienceVaccine, 2017
- Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or OlderNew England Journal of Medicine, 2016
- Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older AdultsNew England Journal of Medicine, 2015
- Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled StudyThe Journal of Infectious Diseases, 2014
- Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 YearsClinical Infectious Diseases, 2012
- Zoster Vaccine: Current Status and Future ProspectsClinical Infectious Diseases, 2010
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsNew England Journal of Medicine, 2005
- Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventoryThe Journal of Pain, 2004
- Clinical manifestations of herpes zoster2000
- The Nature of Herpes Zoster: A Long-Term Study and a New HypothesisProceedings of the Royal Society of Medicine, 1965